Milestone Pharmaceuticals Inc. (MIST)
Milestone Pharmaceuticals Inc.
1111 Dr. Frederik-Philips Boulevard
Suite 420
Montreal, QC H4M 2X6
Canada
514 336 0444
https://www.milestonepharma.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 47
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Joseph G. Oliveto M.B.A. | CEO, President & Director | 949.47k | N/D | 1968 |
| Mr. Amit Hasija | CFO & Executive VP of Corporate Development | 634.89k | N/D | 1973 |
| Dr. David B. Bharucha FACC, M.D., Ph.D. | Chief Medical Officer | 691.43k | N/D | 1962 |
| Dr. Philippe Douville M.B.A., Ph.D. | Founder, Strategic Advisor & Member of Scientific Advisory Board | N/D | N/D | 1962 |
| Mr. Jeffrey Nelson | Chief Operating Officer | N/D | N/D | 1981 |
| Ms. Kim Fox | Vice President of Communications | N/D | N/D | N/D |
| Dr. Philip T. Sager FACC, FAHA, FHRS, M.D. | Chief Medical Advisor & Member of the Scientific Advisory Board | N/D | N/D | 1956 |
| Dr. Guy Rousseau | SVP of Regulatory Affairs and Quality Management | N/D | N/D | N/D |
| Ms. Anita Holz | VP & Head of Medical Affairs | N/D | N/D | N/D |
Descripción
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
Gestión corporativa
La calificación ISS Governance QuickScore de Milestone Pharmaceuticals Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
